Cadila Healthcare is currently trading at Rs. 436.40, up by 26.25 points or 6.40% from its previous closing of Rs. 410.15 on the BSE.
The scrip opened at Rs. 423.00 and has touched a high and low of Rs. 451.15 and Rs. 418.55 respectively. So far 678186 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 451.15 on 03-Nov-2020 and a 52 week low of Rs. 212.70 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 451.15 and Rs. 405.00 respectively. The current market cap of the company is Rs. 44967.89 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.88% and 8.05% respectively.
Zydus has declared that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually from November 13-16, 2020.
Saroglitazar Mg is in various stages of clinical trials to evaluate the safety, tolerability, and efficacy in patients with Primary Biliary Cholangitis (PBC) and Non Alcoholic Steato Hepatitis (NASH).
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1903.00 |
| Dr. Reddys Labs. | 1353.75 |
| Cipla | 1452.35 |
| Zydus Lifesciences | 1152.90 |
| Lupin | 2489.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: